About Aptevo Therapeutics Inc.
https://www.aptevotherapeutics.comAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
CEO
Marvin L. White
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-30 | Reverse | 1:18 |
| 2025-05-27 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1
About Aptevo Therapeutics Inc.
https://www.aptevotherapeutics.comAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.61M ▲ | $-7.55M ▼ | 0% | $-40.13 ▲ | $-7.5M ▼ |
| Q2-2025 | $0 | $6.23M ▼ | $-6.2M ▲ | 0% | $-151.29 ▲ | $-6.18M ▲ |
| Q1-2025 | $0 | $6.48M ▲ | $-6.41M ▼ | 0% | $-1.58K ▼ | $-6.42M ▼ |
| Q4-2024 | $0 | $6.31M ▲ | $-6.31M ▼ | 0% | $-1.56K ▲ | $-6.31M ▼ |
| Q3-2024 | $0 | $5.21M | $-5.1M | 0% | $-6.44K | $-5.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $21.06M ▲ | $27M ▲ | $9.6M ▲ | $17.39M ▲ |
| Q2-2025 | $9.41M ▲ | $15.62M ▲ | $9.1M ▼ | $6.52M ▲ |
| Q1-2025 | $2.14M ▼ | $8.34M ▼ | $9.81M ▼ | $-1.47M ▼ |
| Q4-2024 | $8.71M ▲ | $15.59M ▲ | $10.84M ▲ | $4.75M ▲ |
| Q3-2024 | $7.75M | $15.15M | $10.73M | $4.42M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.55M ▼ | $-6.69M ▲ | $0 | $18.34M ▲ | $11.65M ▲ | $-6.69M ▲ |
| Q2-2025 | $-6.2M ▲ | $-7.09M ▼ | $0 | $14.36M ▲ | $7.27M ▲ | $-7.09M ▼ |
| Q1-2025 | $-6.41M ▼ | $-6.58M ▼ | $0 | $0 ▼ | $-6.58M ▼ | $-6.58M ▼ |
| Q4-2024 | $-6.31M ▼ | $-5.76M ▼ | $0 | $6.72M ▲ | $961K ▲ | $-5.76M ▼ |
| Q3-2024 | $-5.1M | $-5.22M | $0 | $4.91M | $-313K | $-5.22M |
Revenue by Products
| Product | Q2-2018 | Q3-2018 | Q4-2018 |
|---|---|---|---|
 Product | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Marvin L. White
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-30 | Reverse | 1:18 |
| 2025-05-27 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1